SIM SPRING 2016

HEALTH CARE STOCKS EDUARDO MORAES GRANT WILLIAMS LIXIN XU SIYU ZOU




AGENDA

E.F.

1

Service And State

1





THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

er ar



E Fa

The second second second second

ter i

Overview



the second

inger .

SECTOR RECOMMENDATIONS

Healthcare 14.70% of S&P500

3rd largest holding in S&P500

Healthcare 13.06% of SIM fund

4th largest holding in SIM fund

Healthcare 15% of SIM fund

2nd largest holding in SIM fund



THE OHIO STATE UNIVERSITY IER COLLEGE OF BUSINESS

and the second

Overview

E. Se



E Fa

Company Holding	Recommend ation	Weight in SIM Portfolio	Current Price	Target Price	Expected Return
Gilead	Buy	4.14%	\$89.65	\$133.12	48.5 %
McKesson	Buy	4.03%	\$157.41	\$188.24	19.6%
HCA	Neutral	0.00%	\$79.20	\$105	33%
Medtronic	Buy	4.89%	\$75.61	\$83.12	9.94%

The second states of the second states





and the second

14.5

HCA HOLDINGS, INC.

HCA




-



E St.

Hospital Management Company



19-10-11


PERFORMANCE

E. F.



A STATE OF A STATE OF A

1



E. Se



HISTORIC VALUATIONS

HCA Holdings' Historic High, Low, and Current Multiples										
Absolute Basis	High	Low	Median	Current						
P/E (ttm)	17.83	7.06	13.06	15.87						
P/B	N.A	N.A	N.A	N.A						
P/S	1.04	0.33	0.63	0.78						
P/EBITDA	5.21	1.46	3.37	3.89						

a at



THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

-

HCA

E. F.

RELATIVE VALUATION

	Natio	n Wide Indu	istry C	ompetitors for	HCA
Ticker	P/E (ttm)	P/S (ttm)	P/B	P/CF (ttm)	EV/EBITDA (ttm)
Average	11.55	0.55	1.88	8.95	7.67
HCA	15.87	0.78	N.A.	11.06	7.50
LNPT	16.51	0.58	1.31	7.84	7.60
CYH	4.94	0.12	0.55	3.74	6.82
THC	8.19	0.14	3.11	<mark>8.6</mark> 7	8.13
UHS	15.49	1.20	2.56	13.43	8.27



E. F.

a at

North State Party State A

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

tent.

HCA HOLDINGS

DISCOUNTED CASH FLOW

Grant Williams

a star

Terminal Discount Rate = 9.25%

Terminal FCF Growth = 1.50%

Revenue % Growth											
	42,257	45,004	48,154	51,284	54,361	57,215	59,790	62,032	63,893	65,330	66,310
	.2,207	6.50%	7.00%	6.50%	6.00%	5.25%	4.50%	3.75%	3.00%	2.25%	1.509
Operating Income	6,579	7,331	7,936	8,513	9,024	9,498	9,985	10,359	10,670	10,910	11,07 4
Operating Margin	15.57%	16.29%	16.48% <mark></mark>	16.60%	16.60%	16.60%	16.70%	16.70%	16.70%	16.70%	16.70%
Interest and Other	(1,775)	(1,895)	(1,974)	(2,154)	(2,283)	(2,403)	(2,541)	(2,636)	(2,715)	(2,809)	(2,851
Interest % of Sales	-4.20%	-4.21%	-4.10%	-4.20%	-4.20%	-4.20%	-4.25%	-4.25%	-4.25%	-4.30%	-4.309
Taxes	1,530	1,734	1,899	2,026	2,148	2,260	2,372	2,461	2,534	2,581	2,620
Tax Rate	31.85%	31.89%	31.86%	31.86%	31.86%	31.86%	31.86%	31.86%	31.86%	31.86%	31.869
Net Income	3,274	3,703	4,062	4,333	4,593	4,834	5,072	5,262	5,420	5,520	5,603
% Growth	5,274	13.1%	9.7%	6.7%	6.0%	5.2%	4.9%	3.8%	3.0%	1.8%	1.5%
Add Depreciation/Amort	2,028	2,115	2,167	2,180	2,310	2,432	2,541	2,636	2,715	2,777	2,818
% of Sales	4.80%	4.70%	4.50%	4.25%	4.25%	4.25%	4.25%	4.25%	4.25%	4.25%	4.25%
Plus/(minus) Changes WC	(344)	(439)	(440)	(472)	(500)	(526)	(550)	(571)	(588)	(601)	(610
% of Sales	-0.81%	-0.97%	-0.91%	-0.92%	-0.92%	-0.92%	-0.92%	-0.92%	-0.92%	-0.92%	-0.92%
Subtract Cap Ex	2,535	2,745	2,961	3,077	3,126	3,147	3,139	3,102	3,035	2,940	2,818
Capex % of sales	6.00%	6.10%	6.15%	6.00%	5.75%	5.50%	5.25%	5.00%	4.75%	4.50%	4.25%
Free Cash Flow	2,423	2,634	2,828	2,964	3,278	3,593	3,924	4,226	4,513	4,756	4,993
% Growth	_,	8.69%	7.35%	4.82%	10.59%	9.61%	9.23%	7.70%	6.78%	5.38%	4.99%
			High		Low						
NPV of Cash Flows	22,676	46%	22,676	44%	22,676	47%					
NPV of terminal value	26,995	54%	28,928	56%	25,297	53%			Termi	nal Value	65,389
Projected Equity Value	49,671	100%	51,604	100%	47,972	100%					
Free Cash Flow Yield	7.17%								Free C	ash Yield	7.64%
G (D)	12.0		10.5								
Current P/E	12.9	11.5	10.6						1 eri	ninal P/E	11.7
Projected P/E	15.2	13.4	12.2					т			6.0
Current EV/EBITDA Projected EV/EBITDA	7.4 9.2	6. 7 <i>8</i> .4	6.3 7.8					16	rminal EV	EBIIDA	6.8
Trojecieu EV/EBIIDA	9.2	0.4	7.8								
Shares Outstanding Diluted	427										
Current Price	\$ 79.20	High	Low								
Implied equity value/share	\$ 116.40	\$120.93	\$ 112.42								
Upside/(Downside) to DCF	47.0%	52.7%	41.9%								

DCF

HCA

A. A.

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

and the same

SENSITIVITY ANALYSIS

Sensitivity Table of Intrinsic Value Per Share

	Discount Rate											
	\$ 79.20	8.50%	8.75%	9.00%	9.25%	9.50%	9.75%	10.00%				
te	0.75%	\$115.93	\$113.97	\$112.13	\$110.39	\$108.76	\$107.21	\$105.75				
Rate	1.00%	\$118.19	\$116.09	\$114.12	\$112.27	\$110.54	\$108.90	\$107.35				
wth	1.25%	\$120.60	\$118.35	\$116.25	\$114.27	\$112.42	\$110.68	\$109.03				
Growth	1.50%	\$123.18	\$120.76	\$118.51	\$116.40	\$114.42	\$112.57	\$110.82				
0	1.75%	\$125.95	\$123.35	\$120.93	\$118.67	\$116.56	\$114.58	\$112.71				
	2.00%	\$128.94	\$126.13	\$123.52	\$121.10	\$118.83	\$116.71	\$114.73				
	2.25%	\$132.16	\$129.12	\$126.31	\$123.70	\$121.26	\$118.99	\$116.87				



THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

-

HCA

E. F.

No. C. C. Rosen State A

MSKESSON

MCKESSON CORPORATION

McKesson

a at

6.2



ALC: NO

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

BRIEF INTRODUCTION

Founded in 1833



Delivers pharmaceuticals, medical supplies, and health care information technologies to the healthcare industry in the United States and internationally

Two Sectors: Distribution Solutions (90% Revenue) and Technology Solutions

McKesson

Ranked 14th on the FORTUNE 500

The leader in U.S/ International expansion

More than 187 b annual revenue



PERFORMANCE (APR 6, 2015 – APR 1, 2016)

Il McKesson Corporation (NYSE:MCK) - Volume Open: 793,649.00 High: 9.18mm Low: 495,318.00 Close: 937,166.00 Avg: 1.64mm 2015 Sales: 189.13B 250.00 18.00mm **Diluted EPS: 8.36** 17.00mm 240.00 16.00mm **Dividend Yield: 0.71%** 15.00mm 230.00 14.00mm Market Cap: 35.98B 220.00 13.00mm 52-week Range: 148.29 - 243.61 12.00mm 210.00 11.00mm 10.00mm 200.00 9.00mm 190.00 8.00mm 7.00mm 180.00 6.00mm 5.00mm 170.00 4.00mm 160.00 3.00mm 2.00mm 150.00 1.00mm 0.00 May-2015 Jul-2015 Jun-2015 Aug-2015 Sep-2015 Oct-2015 Nov-2015 Dec-2015 Jan-2016 Feb-2016 Mar-2016 Apr-2016 THE OHIO STATE UNIVERSITY McKesson IER COLLEGE OF BUSINESS

McKesson Corporation (NYSE:MCK) - Share Pricing Open: 224.43 High: 242.75 Low: 150.03 Close: 157.41 Avg: 198.33

KEY DRIVERS Connectivity and To create universal access to the healthcare data and improve connectivity **Healthcare Ecosystem** Global Expansion (Celesio) **Acquisitions** New technology or product (Vantage Oncology, LLC and Biologics, Inc.) Reduce operation cost and enlarge synergies **Innovation and** Technology Solution got 1st place in 2014 and 3rd place in 2015 Health care IT giant (Layoff 1,600 employees) Technology Influence Policy to profit from further innovation

McKesson

E Se





E St.

FINANCIAL RATIOS

Profitability analysis	Mar31,2015	Mar 31, 2014	Mar 31, 2013	Mar 31, 2012	Mar 31, 2011	Mar 31, 2010
Return on Sales						
Gross profit margin	6.37%	6.04 %	5.70%	5.35%	5.33%	5.22%
Operating profit margin	1.66%	1.72%	1.89%	1.75%	1.62%	1.85%
Net profit margin	0.82%	0.92%	1.09%	1.14%	1.07%	1.16%
<u>Return on</u> <u>Investment</u>						
Return on equity (ROE)	18.45 %	14.82%	18.93%	20.54%	16.65%	16.77%
Return on assets (ROA)	2.74%	2.44%	3.85%	4.24%	3.89%	4.48 %
Efficiency Analysis	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013	Mar 31, 2012	Mar 31, 2011	Mar 31, 2010
Accounts Receivable Turnover	13.96	12.22	12.28	13.67	13.96	13.72
Inventory Turnover	12.15	10.94	11.32	12.04	11.37	11.47

The second state of the second state

. . .

McKesson

6.2

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

and the

Sec. 1

FINANCIAL RATIOS (CONT'D)

ALL STATISTICS

E. F.

Liquidity Analysis	Mar 31, 2015	5 Mar 31, 2	014 Mar	31, 2013	Mar 31, 2012	Mar 31, 2011	Mar 31, 2010
Current ratio	1.09	1.10		1.08	1.09	1.19	1.26
Quick ratio	63.00%	62.00%	6 58	B.00%	61.00%	68.00%	69.00%
Cash ratio	16.00%	14.00%	6 11	I.00%	15.00%	19.00%	22.00%
DuPont Analysis	ROE	=	Net Profit Margin	×	Asset Turn	iover ×	Leverage
Mar 31, 2015	18.45%		0.82%		3.32		6.73
Mar 31, 2014	14.82%		0.92%		2.66		6.07
Mar 31, 2013	18.93%		1.09%		3.52		4.92
Mar 31, 2012	20.54%		1.14%		3.71		4.84
Mar 31, 2011	16.65%		1.07%		3.63		4.28
Mar 31, 2010	16.77 %		1.16%		3.86		3.74
		McKesson					THE OHIO STATE UNIX FISHER COLLEGE OF BUSINESS

RELATIVE VALUATION

	P/E	P/B	P/S
McKesson	18.70	4.04	0.20
AmerisourceBergen Corporation	50.20	13.89	0.13
Cardinal Health, Inc.	20.20	4.08	0.27

McKesson

E. F.

a at



10.10

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

MULTIPLE VALUATION

Absolute Valuation	Current Multiple	Target Multiple	Target/ Current	Expected EPS	Target Price
P/E	18.70	15.39	0.82	2.51	133.94
P/B	4.04	7.34	1.82	-	295.69
P/S	0.20	0.20	1.00	-	162.75

McKesson

6.2

a at

A DESCRIPTION OF A



14.5

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

DCF VALUATION

6.2

Analyst: Siyu Zou Date: 08/02/2016				minal Disco erminal FCF		9.50% 3.00%					
Year	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E
Revenue	192,250	203,798	214,466	225,190	236,449	248,272	260,685	271,113	281,957	290,416	299,128
% Grow th		6.0%	5.2%	5.0%	5.0%	5.0%	5.0%	4.0%	4.0%	3.0%	3.0%
Operating Income	3,523	3,531	3,716	4,053	4,256	4,469	4,953	5,151	5,357	5,518	5,683
Operating Margin	1.8%	1.7%	1.7%	1.8%	1.8%	1.8%	1.9%	1.9%	1.9%	1.9%	1.9%
	(0.0.0)	(050)	(070)	(150)	(170)		(50.0)	(5.10)	(50.0)	(52.1)	(500
Interest and Other	(332)	(352) -0.2%	(370) -0.2%	(450) -0.2%	(473) -0.2%	(497) -0.2%	(521) -0.2%	(542) -0.2%	(564) -0.2%	(581) -0.2%	(598 -0.2%
Interest % of Sales	-0.276	-0.276	-0.276	-0.276	-0.276	-0.276	-0.2%	-0.276	-0.2%	-0.276	-0.27
Taxes	894	436	629	1,009	1,059	1,112	1,241	1,290	1,342	1,382	1,424
Tax Rate	28.0%	28.0%	28.0%	28.0%	28.0%	28.0%	28.0%	28.0%	28.0%	28.0%	28.0%
Net Income	2,298	2,289	2,409	2,594	2,724	2,860	3,191	3,318	3,451	3,555	3,661
% Grow th	2,200	-0.4%	5.2%	7.7%	5.0%	5.0%	11.6%	4.0%	4.0%	3.0%	3.0%
Add Depreciation/Amort	952	1,019	1,072	1,126	1,182	1,241	1,303	1,084	1,128	1,162	1,197
% of Sales	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.4%	0.4%	0.4%	0.4%
Plus/(minus) Changes WC % of Sales	(826) -0.4%	<mark>(240)</mark> -0.1%	<mark>(222)</mark> -0.1%	(225) -0.1%	(236) -0.1%	(248) -0.1%	(261) -0.1%	(271) -0.1%	(282) -0.1%	(290) -0.1%	(299 -0.1%
Subtract Cap Ex	379	408	429	450	709	745	782	813	846	871	897
Capex % of sales	0.2%	0.2%	0.2%	0.2%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Free Oral Flam	0.044	0.000	0.000	0.045	0.000	0.400	0.454	0.010	0.454	0.555	0.004
Free Cash Flow % Grow th	2,044	2,660 30.1%	2,830 6.4%	3,045 7.6%	2,960 -2.8%	3,108 5.0%	3,451 11.0%	3,318 -3.9%	3,451 4.0%	3,555 3.0%	3,661 3.0%
		30.176	0.4%	7.076	-2.8%	5.0%	11.0%	-3.9%	4.0%	3.0%	3.07
NPV of Cash Flows	19,621	46%									
NPV of terminal value	23,411	54%							Tern	ninal Value	58,018
Projected Equity Value	43,032	100%									
Free Cash Flow Yield	5.68%								Free	Cash Yield	6.31%
Current P/E	15.7	15.7	14.9						т	erminal P/E	15.8
Projected P/E	18.7	18.8	17.9								
Current EV/EBITDA	9.2	9.1	8.6						Terminal	EV/EBITDA	9.2
Projected EV/EBITDA	10.8	10.6	10.1								
Shares Outstanding	229										
Current Price	\$ 157.41										
Implied equity value/share	\$ 188.24										
Upside/(Downside) to DCF	19.6%										
Debt	8,720										
Cash	3,410										
Cash/share	14.92										
			McKes	con							
			meres								

1

A SHARE THE REPORT OF A SHARE A SHARE

THE OHIO STATE UNIVERSITY
 FISHER COLLEGE OF BUSINESS

and the

Sec. 1

SENSITIVITY ANALYSIS

\$188.24	0.070	0.075	0.080	0.085	0.090	0.095	0.100	0.105	0.110
0.015	246.88	225.77	207.92	192.63	179.40	167.83	157.63	148.57	140.47
0.020	262.72	238.42	218.19	201.08	186.42	173.72	162.62	152.83	144.13
0.025	282.08	253.61	230.33	210.93	194.52	180.46	168.28	157.62	148.23
0.030	306.28	272.18	244.90	222.58	203.98	188.24	174.75	163.06	152.83
0.035	337.39	295.38	262.70	236.55	215.15	197.31	182.21	169.27	158.05

Same Star Part Star

McKesson

E. F.



and the

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

tent.

RECOMMENDATION - BUY

a at

E Fa

Company Holding	Recommend ation	Recommended weight	Current Price	Target Price	Expected Return
McKesson	Buy	4.1%	\$157.41 (April 1, 2016)	\$188.24	19.6%



A SHARE THE PARTY AND A SHARE

1.81

Medtronic

MEDTRONIC PLC

A. P.

Medtronic

a star



No.

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

Head.

BRIEF INTRODUCTION



World's largest medical devices manufacturing company, operating in over 440 locations across 155 countries.

Four Business Segments: Cardiac & Vascular Group (35% of Revenues) Minimally Invasive Therapies Group (33% of Revenues) Restorative Therapies Group (25% of Revenues) Diabetes Group (7% of Revenues)

Acquired/Merged with Covidien and moved its headquarters to Dublin, Ireland

Market Cap: \$105 Billion

Medtronic



THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

PERFORMANCE (APR 6, 2015 – APR 1, 2016)

2015 Sales: 25.82B Diluted EPS: 1.75 Dividend Yield: 1.50% Market Cap: 105B 52-week Range: 55.54 – 79.08

Apr 06, 2015 - Apr 05, 2016 • MDT

E. Se



THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

and the second

Medtronic

KEY DRIVERS

Synergies from Covidien Merger

- Cost savings from combining administrative and back-office operations;
- Consolidating manufacturing plants and information technology systems.

Product Portfolio & Global Reach


- Extremely diversified product portfolio (>53,000 patents);
- The firm makes extensive use of economies of scale;
- Global presence allows the company to offset demand elasticity.

Tax Savings & Improved Cash Flows

12.5% Corporate tax rate in Ireland VS 35% Corporate tax rate in the U.S.
This tax inversion will generate tax savings worth over \$800 Million a year.

Medtronic





FINANCIAL RATIOS

6.2

Profitability analysis	2011	2012	2013	2014	2015
Return on Sales					
Gross profit margin	75.45%	75.97%	75.13%	74.52%	68.86%
Operating profit margin	24.74%	26.53%	26.53%	22.42%	18.59%
Net profit margin	19.43%	22.35%	20.90%	18.02%	13.20%
<u>Return on</u> Investment					
Return on equity (ROE)	19.39%	21.14%	18.57%	15.76%	5.03%
Return on assets (ROA)	10.18%	10.93%	9.95%	8.08%	2.51%

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

and the

Sec. 1

Medtronic

A DESCRIPTION AND

RELATIVE VALUATION

Medtronic Company Valuation							
Relative to Industry	7						
	High	Low	Median	Current			
Price / Earnings	0.5	0.7	0.6	0.9			
Price / Book	0.9	0.9	0.8	0.5			
Price / Sales	0.9	0.9	1.1	1.1			
Price / EBITDA	1.1	0.6	0.8	1.3			
Relative to S&P 500)						
	High	Low	Median	Current			
Price / Earnings	1.1	0.8	0.9	1.5			
Price / Book	2.1	1.1	1.2	0.8			
Price / Sales	3.3	3.0	2.3	2.3			
Price / EBITDA	1.9	1.0	1.1	1.6			

Source: Bloomberg, January 2016.

1

6.5

Medtronic



100.00

er ar

MULTIPLE VALUATION

Absolute Valuation	High	Low	Median	Current	Target Multiple	Price Target
P/E	26.3	10	15.3	25.8	29	\$84.90
P/B	6.2	1.8	3	2	2.6	\$96.67
P/S	6.2	2.2	3.4	3.8	3.6	\$70.76
P/EBITDA	24 .1	6.9	12	19.6	19	\$73.41



6.5

Medtronic

Same Star Part Star



10.10

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

DCF VALUATION

E. F.

Medtronic Discounted Cash Flow Valuation											
				al Discour		9.0% 3.50%					
Year	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E
Revenue	26,067	27,207	28, 194	29,321	30,465	31,623	32,793	33,973	35,162	36,393	37,667
% Grow th	29.00%	4.4%	3.6%	4.0%	3.9%	3.8%	3.7%	3.6%	3.5%	3.5%	3.5%
Operating Income	5,888	6,988	6,593	7,004	7,277	7,553	7,833	8,115	8,399	8,693	8,997
Operating Margin	22.6%	25.7%	23.4%	23.9%	23.9%	23.9%	23.9%	23.9%	23.9%	23.9%	23.9%
Interest and Other	(719)	(989)	(1,112)	(1,010)	(1,050)	(1,090)	(1,130)	(1,171)	(1,211)	(1,254)	(1,298)
Interest % of Sales	-2.8%	-3.6%	-3.9%	-3.4%	-3.4%	-3.4%	-3.4%	-3.4%	-3.4%	-3.4%	-3.4%
Taxes	846	938	934	838	871	904	937	971	1,005	1,040	1,077
Tax Rate	14.4%	13.4%	14.2%	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%	14.0%
Net Income	4,323	5,061	4,548	5,155	5,356	5,560	5,766	5,973	6,182	6,399	6,623
% Grow th	22%	17.1%	-10.1%	13.4%	3.9%	3.8%	3.7%	3.6%	3.5%	3.5%	3.5%
Add Depreciation/Amort	1,216	1,255	1,350	1,368	1,421	1,475	1,530	1,585	1,640	1,698	1,757
% of Sales	4.7%	4.7%	4.7%	4.7%	4.7%	4.7%	4.7%	4.7%	4.7%	4.7%	4.7%
Plus/(minus) Changes WC	(33)	(254)	(315)	(293)	(396)	(443)	(328)	(408)	(316)	(328)	(339)
% of Sales	-0.1%	-0.9%	-1.1%	-1.0%	-1.3%	-1.4%	-1.0%	-1.2%	-0.9%	-0.9%	-0.9%
Subtract Cap Ex	700	900	844	787	818	849	881	912	944	977	1,011
Capex % of sales	2.7%	2.7%	2.7%	2.7%	2.7%	2.7%	2.7%	2.7%	2.7%	2.7%	2.7%
Free Cash Flow	4,806	5,162	4,739	5,443	5,563	5,743	6,087	6,238	6,562	6,792	7,029
% Grow th		7.4%	-8.2%	14.9%	2.2%	3.2%	6.0%	2.5%	5.2%	3.5%	3.5%

V of Cash Flows	3	7,033	40%	
V of terminal value	5	5,876	60%	
ojected Equity Value	9	2,909	100%	
ee Cash Flow Yield		5.80%		
Irrent P/E		19.2	16.4	18.2
Projected P/E		21.5	18.4	20.4
Irrent EV/EBITDA		15.7	13.6	14.1
Projected EV/EBITDA		17.1	14.8	15.3
nares Outstanding		1,096		
Irrent Price	\$	75.61		1
plied equity value/share	\$ \$	84.81		
oside/(Downside) to DCF		12.2%		l
bt	3	3,752		
ish		4,843		
Cash/share		4.42		
Termina	I Value	132,279		
Free Cas	sh Yield	5.31%		
Termi	inal P/E	20.0		

Terminal EV/EBITDA 15.0



er ar

Medtronic

a ar



SENSITIVITY ANALYSIS

Sensitivity Analysis											
	Discount Rate										
		8.50%	8.75%	9.00%	9.25%	9.50%					
e	3.00%	\$ 87.76	\$ 83.88	\$ 80.33	\$ 77.07	\$ 74.05					
h Rat	3.25%	\$ 90.43	\$ 86.27	\$ 82.47	\$ 79.00	\$ 75.80					
Growth Rate	3.50%	\$ 93.36	\$ 88.88	\$ 84.81	\$ 81.09	\$ 77.69					
0	3.75%	\$ 96.60	\$ 91.75	\$ 87.37	\$ 83.38	\$ 79.74					
	4.00%	\$ 100.20	\$ 94.93	\$ 90.18	\$ 85.89	\$ 81.98					

FISHER COLLEGE OF BUSINESS

Head.

14.5

Medtronic

wanted the Part of the Part

a at

E. F.

RECOMMENDATION - BUY

6.5

Medtronic Pr	rice Target	
Metric	Target Price	Weight
Discounted Cash Flow	\$84.81	50%
Price / Earnings	\$84.90	12.5%
Price / Book	\$96.67	12.5%
Price / Sales	\$70.76	12.5%
Price / EBITDA	\$73.41	12.5%
Projected Target Price	\$83.12	
Current Price	\$75.61	
Potential Upside	9.94%	

Company Holding	Recommend ation	Recommended weight	Current Price	Target Price	Expected Return
Medtronic	Buy	5.0%	\$75.61	\$83.12	9.94%



THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

No.

er ar

Medtronic

Sec.

GILEAD SCIENCES, INC.

1

A SHALL AND A S

A. F.

Gilead Sciences THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

-

New York

BRIEF INTRODUCTION

Founded in 1987

E St.

Biopharmaceutical Company – Commercialized Medicine

HIV, Liver Diseases, Cardiovascular

Went Public in 1992

Leading Position

Over 30 Countries

Gilead Sciences THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

PERFORMANCE

E. C.



Highest: 121.21 (06/23/2015)

Lowest: 82.71 (02/02/2016)

Current Price: 95.57 (04/05/2016)

Gilead Sciences THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

KEY DRIVERS

R&D And Patents

New products and potential product candidates Competitiveness

Acquisitions

Product portfolio

New technology or improvement on technology

Product Driver

E. Se

Antiviral products Cannibalization

Gilead Sciences



FINANCIAL RATIOS

Year	2015	2014	2013	2012	2011
ROE	94.73%	76.23%	26.03%	26.97%	40.63%
ROA	34.93%	34.79%	13.59%	12.12%	16.12%
Gross Margin	87.73%	84.78%	74.48%	74.53%	74.67%
EBITDA Margin	77.23%	72.80%	59.31%	59.47%	59.86%
Operating Margin	68.00%	61.33%	40.39%	41.33%	45.20%
Net Profit Margin	55.47%	48.45%	27.29%	26.53%	33.27%

Seat.

A SHALL AND A SHALL AND

6.2

Gilead Sciences



No.

-

				nal Discour ninal FCF C		10.75% 4.25%					
(million \$)											
Year	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E
Revenue	32,019	31,635	31,476	30,060	29,158	29,129	29,391	29,920	30,788	31,927	33,284
% Grow th		-1.2%	-0.5%	-4.5%	-3.0%	-0.1%	0.9%	1.8%	2.9%	3.7%	4.3%
Operating Income	21,581	21,448	21,215	19,840	19,011	18,963	19,398	19,837	20,659	21,870	22,833
	-	-		-	-	-	-	-	-	-	-
Operating Margin	67.4%	67.8%	67.4%	66.0%	65.2%	65.1%	66.0%	66.3%	67.1%	68.5%	68.6%
Interest and Other	(640)	(569)	(535)	(481)	(408)	(408)	(411)	(509)	(585)	(670)	(732)
Interest % of Sales	-2.0%	-1.8%	-1.7%	-1.6%	-1.4%	-1.4%	-1.4%	-1.7%	-1.9%	-2.1%	-2.2%
Other Income (Expenses)	128	127	157	90	87	87	88	90	123	128	133
% of Sales	0.4%	0.4%	0.5%	0.3%	0.3%	0.3%	0.3%	0.3%	0.4%	0.4%	0.4%
Taxes	3,582	3,571	3,126	3,485	4,093	4,639	4,747	4,832	5,018	5,300	5,525
		-		-	-				-	-	
Tax Rate	17.0%	17.0%	15.0%	18.0%	22.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%
Net Income	17,487	17,434	17,712	15,964	14,598	14,004	14,328	14,586	15,178	16,027	16,709
% Grow th		-0.3%	1.6%	-9.9%	-8.6%	-4.1%	2.3%	1.8%	4.1%	5.6%	4.2%
Add Depreciation/Amort	1,217	1,139	1,070	902	816	757	735	748	800	958	1,065
% of Sales	3.8%	3.6%	3.4%	3.0%	2.8%	2.6%	2.5%	2.5%	2.6%	3.0%	3.2%
Plus/(minus) Changes WC	9,513	282	(16)	(150)	(233)	(291)	(441)	(180)	31	223	333
% of Sales	29.7%	0.9%	-0.1%	-0.5%	-0.8%	-1.0%	-1.5%	-0.6%	0.1%	0.7%	1.0%
Subtract Cap Ex	640	569	535	601	671	728	764	808	831	926	832
Capex % of sales	2.0%	1.8%	1.7%	2.0%	2.3%	2.5%	2.6%	2.7%	2.7%	2.9%	2.5%
Free Cash Flow	27,576	18,286	18,231	16,115	14,510	13,742	13,858	14,347	15,178	16,283	17,274
% Grow th	21,510	-33.7%	-0.3%	-11.6%	-10.0%	-5.3%	0.8%	3.5%	5.8%	7.3%	6.1%
			5.0,0			0.070	0.070	0.070	0.070		0.170
NPV of Cash Flows	95,084	49%									
NPV of terminal value	99,799	51%							Termin	nal Value	277,055
Projected Equity Value	194,884	100%									
Free Cash Flow Yield	21.40%								Free Ca	ash Yield	6.24%
									_		
Current P/E	7.4	7.4	7.3						Tern	ninal P/E	16.6
Projected P/E	11.1	11.2	11.0					_			
Current EV/EBITDA	5.5	5.6	5.6					Τε	erminal EV	//EBITDA	11.5
Projected EV/EBITDA	8.4	8.5	8.6								
Shares Outstanding	1,464										
Current Price	89.65										
Implied equity value/share	133.12										
Upside/(Downside) to DCF	48.50%						VAL	 .			
Debt	9,891										
Cash	12,851										
Cash/share	8.78										

MULTIPLE VALUATION

Multiples	Gilea	d	Average	An	ngen	Celgene		Biogen	
P/E	7.42		15.39	15.40		22.50		16.24	
P/S	4.27		6.37	5.49		9.74		5.98	
P/B	7.53		8.28 4.18			15.74		5.68	
P/CF	7.56		20.81	13.27		41.64		20.75	
EV/EBITDA	5.78		15.32	11.28		33.51		10.70	
Multiples	Max	Min	Average of 3 Peer	Firms	Average o	fIndustry	Denor	ninators	
P/E	22.50	15.40	18.05		15.39	EPS 12		12.37	
P/S	9.74	5.49		7.07		6.37 Sales/Share		are	22.29
P/B	15.74	4.18	8.53		8.28 Book Va		Book Val	ue/Share	35.41
P/CF	41.64	13.27	25.22		20.81 C		Cash Flov	v/Share	12.05
EV/EBITDA	33.51	10.70	18.50			15.32 EBITDA /		hare	17.22
Gilead Value									
P/E*E	278.33	190.50		223.24		190.37			
P/S*S	217.15	122.40	157.62		142.02				
P/B*B	557.34	148.01	302.		293.19				
P/CF*CF	501.70	159.88		303.86	6 250.73				
EV/EBITDA*EBITDA	576.97	184.23		318.47		263.78			

A SHORE END A CONTRACT SHE

Seat.

6.2

Gilead Sciences THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

14.5

ABSOLUTE VALUATION

Multiples	Gilead Multiple	Target Multiple	Target Multiple /Gilead Multiple	Current Price	Target Price	
P/E	7.42	13.50	1.82	89.65	163.11	
P/S	4.27	10.10	2.37	89.65	212.05	
P/B	7.53	8.20	1.09	89.65	97.63	
EV/EBITDA	5.78	10.00	1.73	89.65	155.10	

Gilead Sciences

6.2

Seat.

A SHARE CONTRACTOR AND

THE OHIO STATE UNIVERSITY
 FISHER COLLEGE OF BUSINESS

-

-

14.5

TECHNICAL ANALYSIS



E St.

Downward Price Pressure

Gilead Sciences


A CALL STORE

THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

(Anderson)



E. F.



-

CATALYST

Undervalued in all three valuation approaches

Competitive advantages


E. Se

Fundamental drivers for future increase

Gilead Sciences THE OHIO STATE UNIVERSITY FISHER COLLEGE OF BUSINESS

4-60 d

RECOMMENDATION





The second second second second

1

E Fa



inger .